Specific test panels for patients with heart failure: implementation and use in the Spanish National Health System

https://doi.org/10.1515/almed-2022-0006
Received September 30, 2021; accepted November 17, 2021; published online March 7, 2022

Abstract

Objectives: The use of specific test panels (STP) for heart failure (HF) could help improve the management of this condition. The purpose of this study is to gain an insight into the level of implementation of STPs in the management of HF in Spain and gather the opinions of experts, with a special focus on parameters related to iron metabolism.

Methods: The opinions of experts in HF were gathered in three stages STAGE 1 as follows: level of implementation of STPs (n=40). STAGE 2: advantages and disadvantages of STPs (n=12). STAGE 3: level of agreement with the composition of three specific STPs for HF: initial evaluation panel, monitoring panel, and de novo panel (n=16).

Results: In total, 62.5% of hospitals used STPs for the clinical management of HF, with no association found between the use of STPs and the level of health care (p=0.132) and location of the center (p=0.486) or the availability of a Heart Failure Unit in the center (p=0.737). According to experts, the use of STPs in clinical practice has more advantages than disadvantages (8 vs. 3), with a notable positive impact on diagnostics. Experts gave three motivations and found three limitations to the implementation of STPs. The composition of the three specific STPs for HF was viewed positively by experts.

Conclusions: Although the experts interviewed advocate the use of diagnostic and monitoring STPs for HF, efforts are still necessary to achieve the standardization and homogenization of test panels for HF in Spanish hospitals.

Keywords: diagnosis; healthcare management; heart failure; iron profile; monitoring; test panels.

Introduction

Specific test panels (STPs) are useful to prevent the overutilization and underutilization of laboratory tests and counter the increased demand and cost of healthcare resources [1, 2]. When adjusted to different levels of health care and settings, STPs improve disease control and resource use, reduce costs, homogenize healthcare, and facilitate research. Heart failure (HF) is a clinical syndrome causing shortness of breath, ankle swelling and fatigue which signs include pulmonary crackles, elevated jugular venous pressure and peripheral edema [3]. This pathological condition is the consequence of an anomaly in cardiac structure or function and is considered a major public health problem [3]. The prevalence of HF in adults in developed countries is 2%, increasing dramatically with age, being <1% before 50 years, doubling with each decade, and reaching 8% above 75 years [3]. HF is the leading cause of hospitalization in patients older than 65 and accounts for more than 2% of healthcare expense in Spain. It is also a frequent cause of morbidity and mortality [3–6]. The etiology of HF is multifactorial, with several risk factors being involved [7]. Since iron deficiency is common in patients with HF [8–10], routine iron profile testing (serum ferritin and transferrin saturation) is recommended for all patients with suspected
or confirmed HF [3]. Including iron tests in STPs for HF would ensure compliance with this recommendation. STPs may facilitate the diagnosis and monitoring of HF and its comorbidities. This would improve healthcare quality and clinical outcomes and reduce the direct costs of unnecessary testing and the indirect costs of failing to order appropriate tests. Our primary goal was to evaluate the level of implementation of STPs for HF, a prevalent condition in Spain. Secondary goals included exploring the advantages and disadvantages of STP; assessing whether STPs include the parameters indicated for HF – including iron profile – in the guidelines and interviewing experts in HF about the suitability of three STPs for HF.

Materials and methods

Study design and data collection

The methodological design and field work were performed by the medical agency (MA) Anima Strategic Consulting. Non-probability purposeful sampling was employed to define the study population and perform participant recruitment, taking into account sample dispersion by level of health care, geographical location, and presence of a Heart Failure Unit (HFU) in the center. Emergency care was excluded.

Informed consent was obtained before interviews. The first stage (STAGE 1) included computer-assisted telephone interviewing (CATI) to gather the opinions of cardiologists from different regions in Spain (November–December 2019). STAGE 1 involved a prospective study of the level of automation of laboratory tests and the creation and use of STPs for HF. CATI questionnaires were jointly designed with the MA with yes/no answers. Participants in STAGE 1 were cardiologists with more than five years of experience after their residency attending at least 15 HF patients monthly. Geographical locations, main characteristics, and level of health care of each center according to World Health Organization classification [11] are shown in Supplementary Figure 1. The questionnaire is available in Supplementary Figure 2.

In STAGE 2, experts in STPs were interviewed (May–June 2020). The panel was composed of seven expert cardiologists in HF whose hospitals had integrated a STP for HF, and five clinical laboratory directors (three hospital and two external laboratories) experienced in creating STPs (Supplementary Figure 3). We collected information about STP design process and identified best practices in their implementation in centers of reference. Owing to COVID-19, interviews, designed and conducted by the MA, were performed by video call (see questionnaire in Supplementary Figure 4).

In STAGE 1, the interviewers obtained the results of the CATI questionnaire in real time and, for quality control, reviewed the recordings to verify information. Interviews were then evaluated by a different investigator. Subsequently, another investigator reviewed the analysis of 10 random interviews. Field work results were obtained by joint cross-interview analysis.

STAGE 2 interviews were transcribed verbatim and analyzed as in STAGE 1, except that, for quality purposes, interviews were conducted and transcribed by different consultants. Qualitative analysis was performed by two investigators, who classified and shared answers. Following classification, the same investigators counted the repetitions of each answer.

In STAGE 3, the authors designed three STPs for the clinical management of HF [initial evaluation panel, monitoring panel, and de novo panel (see Supplementary Table 1)]. These STPs were constructed considering the latest scientific evidence and the most commonly assayed laboratory parameters at these three key time points. Sixteen experts in HF discussed the composition and efficacy of these parameters and advocated or opposed to the inclusion of each parameter.

Statistical analysis

Qualitative variables are expressed in absolute values. Differences between groups were analyzed using Chi-square test or Fisher’s exact test. Statistical analysis was performed using GraphPad Prism 9.0 (GraphPad Software, Inc., San Diego, CA).

Results

Level of implementation of STPs for HF

All hospitals had a laboratory information system and used different laboratory analysis request protocols.

Of the 40 hospitals analyzed, 15 (37.5%) had not established a STP for HF, therefore parameters were selected individually (Table 1), whereas 25 (62.5%) employed a specific STP for HF. With just a click, HF-specific parameters were selected.

STAGE 1 did not provide evidence of a correlation between level of automation of laboratory test orders and level of health care (p=0.132; tertiary, secondary or primary level), location (p=0.486; urban or rural) or the presence/absence of a HFU (p=0.737; Table 1).

| Table 1: Types of tests performed in patients with HF by level of health care. |
|-----------------|-----------------|-----------------|-----------------|
| Level of health care | STP Individualized | p-Value |
|-----------------|-----------------|-----------------|-----------------|
| Primary | 3 (7.5) | 0 | 0.132 |
| Secondary | 8 (20) | 9 (22.5) |
| Tertiary | 14 (35) | 6 (15) |
| Rural | 8 (20) | 3 (7.5) | 0.486 |
| Urban | 17 (42.5) | 12 (30) |
| With | 8 (20) | 6 (15) | 0.737 |
| Without | 17 (42.5) | 9 (22.5) |
| Total | 25 (62.5) | 15 (37.5) |

HF, heart failure; STP, specific test panel; Individualized, individualized selection system.
Supplementary Table 2 contains data on the presence of iron profile (IP) tests in STPs or in pre-established parameter sets (in hospitals without STP). IP testing was associated with tertiary level (p=0.048). Neither location nor the availability of a HFU were associated with IP testing in HF patients.

Advantages and disadvantages of STPs

In STAGE 2, cardiologists and laboratory directors described the advantages of STPs (Figure 1), including their scientific relevance, innovative nature, capacity to empower nurses and facilitate effective, correct updated, homogeneous, easy and rapid diagnosis. The most frequently cited advantages were that STPs enable effective, correct easy and rapid diagnosis (eight votes) and homogeneous diagnosis (seven votes).

Disadvantages include a poorer cost-effectiveness if STPs are not correctly designed, the impossibility of sharing them with primary care, and its high demand and low efficacy, being the latter the most frequently cited disadvantage (seven votes; Figure 2).

Incentives and barriers to the establishment of STPs

Motivations for the implementation of STPs included their cost-effectiveness, a clear perception of its benefits, and the simplicity and accessibility of the system (Figure 3), being the last two answers the most frequently cited advantages.

By increasing order of frequency, drawbacks of STPs (Figure 4) include lack of interest in creating a STP, poor relationship and/or communication with the laboratory, and unawareness of the possibility of creating and editing STPs.

A STPs model for the clinical management of HF: the opinions of experts

Table 2 contains the three STPs models developed for HF. Three of the experts consulted (18.75%) did not consider STPs for HF necessary. Two experts had already created other test panels and did not deem it necessary to create new test panels. The other expert opposing to STPs argued that his Cardiology Unit used a general cardiology laboratory profile, which he considered suitable for the clinical management of HF. Most of the 13 experts (81.25%) advocating the use of the three STPs for HF considered their composition suitable.

Regarding Panel 1 (initial evaluation profile), experts unanimously agreed with all the parameters included, except for CA-125 (five opposing votes) and NT-proBNP (two opposing votes). All experts coincided that iron profile tests should be included in Panel 1. There was also unanimity on most of the parameters of Panel 2 (monitoring profile). In this case, two experts opposed to the inclusion of uric acid and NT-proBNP in this profile. Finally, the majority of experts agreed with Panel 3 (de novo profile) composition, although unanimity was only reached on urine.

Discussion

Healthcare management is undergoing the digitization, automation and standardization of processes [12]. Developed
countries have experienced a dramatic rise in health burden and costs, and this tendency is estimated to maintain in the near future [1]. The effective use of standard automated test panels may help reduce costs and improve the clinical management of patients.

This study demonstrates differences in the management and use of laboratory tests and iron profile testing in HF. STPs were available in 62.5% of hospitals vs. 37.5%. There was no association between the use of STPs and level of health care, location, or HFU availability. There was a statically significant difference between protocols for requesting iron profile tests and level of health care. Real clinical practice is inconsistent with the opinions of experts on the three STPs developed. Experts advocated iron profile testing, since iron deficiency is common in HF. This deficiency is associated with poorer physical performance, deterioration of health-related quality of life and a higher risk of mortality, irrespectively of the associated presence or not of anemia [8–10, 13]. The 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of HF [3] recommend routinely testing iron profile in all patients with suspected or confirmed HF. When iron deficiency is detected, supplementation is prescribed resulting in clinical benefits for the patient [14–17]. Iron supplementation in HF is also cost-effective, as demonstrated by Delgado et al. [18]. A meta-analysis conducted by Khan in 2020 [15] and two clinical trials (CONFIRM-HF [17] and AFFIRM-AHF [16]) reveal that the administration of iron carboxymaltose to HF patients reduces the risk of hospitalization, resulting in a reduction of health costs [15–17]. Therefore, iron profile should be routinely tested in HF patients, which STPs could facilitate, since they help translate best practices into real practice.

Experts found more advantages than disadvantages in the integration of STPs, with improvements in diagnosis being the most frequently cited advantage. STPs were considered an easy-to-use, accessible tool, with the experts interviewed having a clear perception of the benefits of this system. The main drawback was unawareness that test panels can be created and/or edited. Experts advocate the use of STPs and find few barriers to their implementation. However, the use of STPs is far from commonplace, possibly due to the fact that health professionals lack the time to develop and implement new protocols [19, 20]. It is necessary to raise awareness on the need to improve strategic planning, which would have positive effects on healthcare management [19, 20].

This study shows inconsistencies in the use and composition of STPs, which hinders cross-site comparison. All experts agreed with the composition of the three STPs proposed, with some divergences on their composition. There was discrepancy concerning the inclusion of CA-125.

### Table 2: STP model for the clinical management of patients with HF and opinions of experts.

**PANEL 1: Initial evaluation test panel**

| Test Panel | In favor | Against |
|------------|----------|---------|
| Glycosylated hemoglobin A1c | 13 | 0 |
| Urea | 13 | 0 |
| Glucose | 13 | 0 |
| Creatinine | 13 | 0 |
| Uric acid | 13 | 0 |
| Total cholesterol | 13 | 0 |
| HDL cholesterol (direct) | 13 | 0 |
| LDL cholesterol (calculated) | 13 | 0 |
| Triglycerides | 13 | 0 |
| AST/GOT | 13 | 0 |
| ALT/GPT | 13 | 0 |
| GGT | 13 | 0 |
| Alkaline phosphatase | 13 | 0 |
| Total bilirubin | 13 | 0 |
| Total proteins | 13 | 0 |
| Albumin | 13 | 0 |
| Ferritin | 13 | 0 |
| Transferrin saturation index (TSI) | 13 | 0 |
| CA125 | 8 | 5 |
| NT-proBNP | 11 | 2 |
| Prothrombin time | 13 | 0 |
| INR | 13 | 0 |
| Hemogram | 13 | 0 |

**PANEL 2: Monitoring test panel**

| Test Panel | In favor | Against |
|------------|----------|---------|
| Urea | 13 | 0 |
| Glucose | 13 | 0 |
| Creatinine | 13 | 0 |
| Uric acid | 13 | 0 |
| AST/GOT | 13 | 2 |
| ALT/GPT | 13 | 0 |
| GGT | 13 | 0 |
| Alkaline phosphatase | 13 | 0 |
| Total bilirubin | 13 | 0 |
| Total proteins | 13 | 0 |
| Albumin | 13 | 0 |
| Ions (Na, K, Cl) | 13 | 0 |
| NT-proBNP | 11 | 2 |
| Prothrombin time | 13 | 0 |
| INR | 13 | 0 |
| Hemogram | 13 | 0 |

**PANEL 3: De novo test panel**

| Test Panel | In favor | Against |
|------------|----------|---------|
| Thyroid hormones (TSH) | 11 | 2 |
| High-sensitivity troponin (T or I) | 12 | 1 |
| CRP (C reactive protein) | 12 | 1 |
| Urine metanephrines | 11 | 2 |
| Urine (sediment abnormalities, proteinuria) | 13 | 0 |

HF, heart failure; STPs, specific test panels. *Free T4 and free T3 in the presence of TSH alteration. †Consider indication.
in Panel 1. Although there is consistent scientific evidence supporting its inclusion in laboratory tests for HF, it is rarely mentioned in clinical guidelines [21, 22]. There were some minor discrepancies concerning the inclusion of NT-proBNP in Panels 1 and 2. The 2021 ESC guidelines do recommend the inclusion of NT-proBNP in the laboratory profile for HF [3]. However, experts did not consider it necessary to test NT-proBNP in all patients. Three experts in STAGE 3 deemed that Panel 3 parameters (thyroid hormones, cardiac troponin measured by high sensitivity method, CRP and plasma metanephrines) should be integrated into Panel 1. Experts would only order a urine test (sediment, proteinuria) in the monitoring laboratory test of hospitalized patients. The three STPs proposed are a starting point in terms of content and number, and may help design consensus recommendations for the use of STPs in HF.

Limitations of this study include sample size, if we consider the number of health professionals involved in the management of HF in Spain. Nevertheless, this sample is representative of health professionals in Spain, as it includes hospitals of different levels of care, locations and with and without HFU. Another limitation is the use of CATI for data collection, which could be affected by the absence of visual signals and data loss and distortion [23, 24]. However, CATI is a widely-accepted data collection tool in clinical practice, public health research and epidemiology, as it enables gathering large data sets and managing sensitive information [23].

In conclusion, the implantation of STPs is still very limited in Spain. However, most of the healthcare professionals interviewed consider that STPs are useful for the homogenization and standardization of STPs for HF and advocate their implementation and use. It is necessary to improve communication and coordination between laboratory and cardiology services. Likewise, modern technologies may help improve laboratory test ordering through STPs for the clinical management of HF.

Acknowledgments: We would like to thank Anima Strategic for the field work conducted as well as the medical editorial services. Also, we would like to thank a Vifor Pharma for providing us this service.

Research funding: None declared.

Author contribution: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: Authors state no conflict of interest.

Informed consent: Informed consent was obtained from all individuals included in this study.

Ethical approval: The local Institutional Review Board deemed the study exempt from review.

References

1. Dieleman JL, Campbell M, Chapin A, Eldenkamp E, Fan YY, Haakenstad A, et al. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet 2017;389:2005–30.

2. Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS One 2013;8:e78962.

3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bühm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726.

4. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure – the Rotterdam Study. Eur Heart J 2004;25:1614–9.

5. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137–46.

6. Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Comín-Colet J, et al. Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardíaca crónica sintomática en España. Rev Española Cardiol 2014;67:643–50.
7. Inamdar AA, Inammdar AC. Heart failure: diagnosis, management and utilization. J Clin Med 2016;5:62.
8. McDonagh T, Damy T, Doehner W, Lam CSPP, Sindone A, van der Meer P, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology Heart Failure Guidelines into Clinical Practice. Eur J Heart Fail 2018;20:1664–72.
9. Cohen-Solal A, Leclercq C, Deray G, Lasocki S, Zambrowski JJ, Mebazaa A, et al. Iron deficiency: an emerging therapeutic target in heart failure. Heart 2014;100:1414–20.
10. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 2018;138:80–98.
11. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization; 2003.
12. Neumaier M. Diagnostics 4.0: the medical laboratory in digital health. Clin Chem Lab Med 2019;57:343–8.
13. Comín-Colet J, Martín Lorenzo T, González-Domínguez A, Oliva J, Jiménez Merino S. Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. Health Qual Life Outcome 2020;18:329.
14. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016;18:786–95.
15. Anker SD, Kirwan B-A, van Veldhuisen DJ, Filippatos G, Comín-Colet J, Ruschitzka F, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125–33.
16. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet (London, England) 2020;396:1895–904.
17. Ponikowski P, van Veldhuisen DJ, Comín-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–68.
18. Delgado JF, Oliver J, González-Franco A, Cepe da JM, García-García JA, González-Domínguez A, et al. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. J Med Econ 2020;23:1418–24.
19. Gordon CE, Borkan SC. Recapturing time: a practical approach to time management for physicians. Postgrad Med J 2014;90:267–72.
20. Strategic planning: why it makes a difference, and how to do it. J Oncol Pract. 2009;5:139–43.
21. Li KHC, Gong M, Li G, Baranchuk A, Liu T, Wong MCSS, et al. Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia 2018;10:e011044.
22. Vizzardi E, D’Alola A, Curnis A, Dei Cas L. Carbohydrate antigen 125: a new biomarker in heart failure. Cardiol Rev 2013;21:23–6.
23. Novick G. Is there a bias against telephone interviews in qualitative research? Res Nurs Health 2008;31:391–8.
24. Kreuter F, Presser S, Tourangeau R. Social desirability bias in CATI, IVR, and web surveys: the effects of mode and question sensitivity. Publ Opin Q 2009;72:847–65.
25. Huck A, Lewandrowski K. Utilization management in the clinical laboratory: an introduction and overview of the literature. Clin Chim Acta 2014;427:111–7.
26. Smellie WSA. Demand management and test request rationalization. Ann Clin Biochem 2012;49:323–36.
27. Krasowski MD, Chudzik D, Dolezal A, Siesussy B, Gailey MP, Koch B, et al. Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center. BMC Med Inf Decis Making 2015;15:11.
28. Lapić I, Juroš GF, Rako I, Rogić D. Changing the electronic request form proves to be an effective tool for optimizing laboratory test utilization in the emergency department. Int J Med Inform 2017;102:29–34.
29. Thomas RE, Vaska M, Naugler C, Turin TC. Interventions at the laboratory level to reduce laboratory test ordering by family physicians: systematic review. In: Clinical biochemistry. Elsevier Inc.; 2015, vol. 48:1358–65 pp.
30. Seppänen K, Kauppila T, Piltäälï K, Kautiainen H, Puustinen R, livanainen A, et al. Altering a computerized laboratory test order form rationalizes ordering of laboratory tests in primary care physicians. Int J Med Inform 2016;86:49–53.
31. Feldman LS, Shihab HM, Thiemann D, Yeh H-CC, Ardolino M, Mandell S, et al. Impact of providing fee data on laboratory test ordering: a controlled clinical trial. JAMA Intern Med 2013;173:903–8.
32. Eaton KP, Levy K, Soong C, Pahwa AK, Petrilli C, Ziemba JB, et al. Evidence-based guidelines to eliminate repetitive laboratory testing. JAMA Intern Med 2017;177:1833–9.
33. Iams W, Heck J, Kapp M, Leverenz D, Vella M, Szentirmai E, et al. A multidisciplinary housestaff-led initiative to safely reduce daily laboratory testing. Acad Med 2016;91:813–20.
34. Sedrak MS, Myers JS, Small DS, Nachamkin I, Ziemba JB, Murray D, et al. Effect of a price transparency intervention in the electronic health record on clinician ordering of inpatient laboratory tests: the PRICE randomized clinical trial. JAMA Intern Med 2017;177:939–45.
35. Vidyarthi AR, Hamill T, Green AL, Rosenbluth G, Baron RB. Changing resident test ordering behavior: a multilevel intervention to decrease laboratory utilization at an academic medical center. Am J Med Qual 2015;30:81–7.
36. Kobewka DM, Ronksley PE, McKay JA, Forster AJ, Van Walraven C. Influence of educational, audit and feedback, system based, and incentive and penalty interventions to reduce laboratory test utilization: a systematic review. In: Clinical chemistry and laboratory medicine. Walter de Gruyter GmbH; 2015, vol. 53: 157–83 pp.
37. SEC • SEMI • SEMES. Consenso para la mejora de la atención integral de los pacientes con Insuficiencia Cardiaca Aguda; 2014.

**Supplementary Material:** The online version of this article offers supplementary material (https://doi.org/10.1515/almed-2022-0006).

**Article Note:** The original article can be found here: https://doi.org/10.1515/almed-2021-0076.